1. In Vivo
  2. >>Innovation

The Role Of Data Encryption In Cyber Attacks

 
• By Nigel Thorpe

The health care and pharma industries are particularly vulnerable to a cyber-attack, also experiencing the highest cost of a breach. New ways of seamlessly encrypting data may be the way forward.    

Cybersecurity
• Source: Shutterstock

The pharmaceutical industry is certainly no stranger to cyber-attacks. Merck & Co., Inc.'s 2017 'NotPetya' cyberattack is still looming large over the industry, as the legal ramifications - including Merck's $1.4bn insurance claim – continue into 2023. (Also see "Merck Cyberattack Recovery: Congress Scrutinizes Manufacturing Problems" - Pink Sheet, 21 September, 2017.)

More recently, AstraZeneca PLC is in the spotlight for a data breach which saw credentials for one of its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

How Rapport Transferred A Decade Of Big Pharma Neuroscience Expertise To Biotech

 
• By David Wild

Rapport Therapeutics CEO discusses the company's novel approach to AMPA modulation and why strategic externalization from J&J is accelerating neuroscience innovation.

Podcast: Merck’s Vision For Making Digital Health Redundant

 
• By Jo Shorthouse

Merck KGaA's Emre Ozcan outlines the company's systematic approach to integrating digital solutions across the care continuum in specialty pharmaceuticals, moving from technology-first to patient-need-first strategies.

Does ReproNovo’s $65m Raise Signal An Oasis In The Fertility Investment Desert?

 
• By Jo Shorthouse

ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.

Moderna Veteran Launches Icelandic mRNA Firm Despite US Retreat

 
• By David Wild

Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

More from In Vivo

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By David Wild

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Deals In Depth: July 2025

 
• By Deanna Kamienski and Maureen Riordan

Six $1bn+ alliances were penned in July, and two exceeded $2bn.

Execs On The Move: July 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.